Thermo Fisher Scientific Statistics & Facts 2026

By Emily Martin

Thermo Fisher Scientific Inc. is one of the world’s largest providers of life-science tools, laboratory products, analytical instruments, specialty diagnostics, clinical research services and pharmaceutical manufacturing services. The company is headquartered at 168 Third Avenue in Waltham, Massachusetts, and trades on the New York Stock Exchange under TMO.

The present company was created in 2006 through the merger of Thermo Electron and Fisher Scientific, although its predecessor businesses extend much further back. Thermo Fisher matters because its reagents, instruments, distribution channels and outsourced services sit inside essential workflows across biopharma R&D, clinical trials, diagnostics, academic research, industrial quality control and medicine manufacturing. This breadth also creates a highly recurring revenue profile: services and consumables represented 84% of the 2025 portfolio profile.

Key Highlights

Company profile and 2026 snapshot

Key Statistics

• FY2025 revenue increased 3.9% to $44.556 billion from $42.879 billion.
• Attributable net income rose 5.8% to $6.704 billion in 2025.
• GAAP operating income climbed 5.6% to $7.746 billion, producing a 17.4% margin.
• GAAP diluted EPS increased 7.3% to $17.74; adjusted EPS reached $22.87.
• The company generated $7.818 billion in operating cash flow and $6.337 billion in free cash flow in 2025.
• R&D spending was $1.397 billion, equivalent to 3.1% of revenue.
• Capital expenditure reached $1.525 billion, up 8.9% year over year.
• Approximately 125,000 colleagues worked globally at year-end 2025.
• The workforce included about 59,000 in the Americas, 44,000 in EMEA and 22,000 in Asia-Pacific.
• Thermo Fisher employed about 14,000 sales personnel, including technical specialists.
• Laboratory Products and Biopharma Services generated $23.984 billion of segment revenue before eliminations.
• The Life Sciences Solutions segment grew 7.7% to $10.374 billion.
• Services and consumables represented 84% of the revenue profile; instruments represented 16%.
• Pharma and biotech customers represented 57% of the 2025 end-market profile.
• North America represented 52% of the regional revenue profile, Europe 26%, Asia-Pacific 18% and the rest of world 4%.
• First-half 2026 revenue was $23.00 billion, approximately 8.4% above the prior-year period.
• Q2 2026 revenue grew 10% to $11.99 billion, including 5% organic growth.
• Thermo Fisher repurchased $4.0 billion of shares during the first two quarters of 2026.
• The company sourced 47% of electricity from renewable sources in 2024, the latest detailed CSR year available.
• 2024 Scope 3 emissions were 8.402 million metric tons CO2e, down 12.1% year over year.

Revenue Statistics

Revenue growth, FY2021–FY2025

Revenue returned to clearer expansion in 2025 after the post-pandemic normalization seen in 2023 and the nearly flat result in 2024. Currency translation added approximately $0.37 billion in 2025, while organic revenue grew 2%.

2026 quarterly revenue update

Net Income Statistics

Net income attributable to Thermo Fisher

Net income expanded faster than revenue in 2025. The reported tax rate was unusually low at 7.5%, aided by discrete deferred-tax benefits; this should be considered when comparing recurring profitability.

Operating Income Statistics

GAAP operating income

Gross Margin Statistics

Calculated gross profit and margin

The 2025 gross margin eased by about 0.4 percentage points, reflecting business mix, tariffs and acquisition effects, while productivity helped operating margin improve.

EBITDA Statistics

Calculated EBITDA proxy

R&D Spending Statistics

Research and development trend

R&D remained near $1.4 billion, supporting product launches in mass spectrometry, electron microscopy, PCR, bioproduction and diagnostics. The scale of spending is important, but innovation also comes from acquired technology platforms.

Capital Expenditure Statistics

Purchases of property, plant and equipment

Regional Revenue Statistics

2025 regional revenue profile

A separate SEC geography table reports U.S. revenue of $22.240 billion and all other countries at $22.316 billion. Because the company does not publish stand-alone Latin America or Middle East & Africa revenue, those values should not be presented as exact company statistics.

Business Segment Statistics

2025 segment performance before eliminations

Laboratory Products and Biopharma Services is the largest revenue segment, while Life Sciences Solutions has the highest segment margin. Its 2025 growth was led by bioproduction, including contributions from the acquired filtration and separation business.

Product Category Statistics

Portfolio and end-market mix

Thermo Fisher does not disclose revenue for individual products. Consequently, claims about a single ‘largest product’ or exact product-level market share are not verifiable from public filings. The strongest disclosed growth signals in 2025 came from bioproduction, pharma services, the research and safety channel, clinical diagnostics, immunodiagnostics and transplant diagnostics.

Geographic Presence and Employees

2025 workforce distribution

The company reports operations and a taxable presence in approximately 70 countries outside the United States. It does not provide a single audited count of manufacturing plants or distribution centers in the 10-K. Facilities span manufacturing, laboratories, offices, clinical-research operations, distribution and customer-facing innovation centers.

Employee and Diversity Statistics

Selected workforce indicators

ESG Statistics

Selected environmental indicators

Water consumption, waste diversion and safety metrics are included in the CSR reporting suite, but the most recent detailed data year available during this report’s preparation was 2024. Readers should avoid relabeling 2024 ESG values as 2026 performance.

Innovation Statistics

Innovation evidence, 2025–H1 2026

Acquisition Statistics

Selected recent transactions

Manufacturing and Digital Transformation

Operations and digital initiatives

Market Share Statistics

Market-position disclosure

A defensible market-share article should use narrowly defined third-party datasets for each category—mass spectrometry, electron microscopy, life-science reagents, clinical research or CDMO services—because a single global share would combine fundamentally different markets.

Competitor Comparison

Selected peer comparison

Stock Performance Statistics

TMO shareholder metrics

Five-year share-price returns depend on the exact start date, dividend treatment and closing-price source. For publication, pair this table with an exchange-licensed price series rather than estimating a trend from isolated snapshots.

Financial Ratios

Calculated FY2025 ratios

SWOT Analysis

Thermo Fisher SWOT

Recent Developments

Timeline of material developments

Interesting Facts

• The current Thermo Fisher entity was formed in 2006, but Fisher Scientific traces its roots to 1902.
• The company’s mission is to enable customers to make the world healthier, cleaner and safer.
• More than half of the 2025 end-market profile came from pharma and biotech customers.
• Only 16% of the revenue profile was instruments; recurring services and consumables made up 84%.
• The U.S. and all other countries each contributed almost exactly half of 2025 revenue.
• Thermo Fisher had about 14,000 sales personnel—roughly one in nine colleagues.
• Life Sciences Solutions delivered a 36.3% segment income margin in 2025.
• The company returned $3.6 billion through buybacks and dividends in 2025.
• It repurchased another $4.0 billion in shares during H1 2026.
• Free cash flow exceeded $6.3 billion in 2025.
• The company committed about $13 billion to M&A during 2025.
• Clario deepens the PPD clinical-research platform with endpoint data.
• The Oncomine Dx Express workflow can produce results in as little as 24 hours, according to the annual report.
• Thermo Fisher collaborated with OpenAI in 2025 and NVIDIA in 2026.
• Q2 2026 included next-generation Orbitrap systems with AI-driven analytics.
• The company supports customers from basic research through commercial drug manufacturing.
• The PPI Business System is Thermo Fisher’s company-wide continuous-improvement framework.
• Renewable electricity reached 47% of global electricity use in 2024.
• Eighty sites used 100% renewable electricity by year-end 2024.
• Thermo Fisher has a taxable presence in roughly 70 countries outside the United States.